Patents by Inventor Yang-Xin Fu

Yang-Xin Fu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sting activating nanovaccine for immunotherapy
    Patent number: 11376324
    Abstract: In some aspects, the present disclosure provides vaccine compositions comprising an antigen and a diblock copolymer wherein the diblock copolymer is pH responsive. In some embodiments, these compositions activate the STING and/or the interferon receptor pathways. In some embodiments, the diblock copolymer hits a pKa from about 6 to about 7.5. Also provided herein are methods of treatment using these compositions to treat an infectious disease or cancer.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: July 5, 2022
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Jinming Gao, Zhijian Chen, Min Luo, Zhaohui Wang, Hua Wang, Haocheng Cai, Gang Huang, Yang-Xin Fu
  • INTERLEUKIN 12 FUSION PROTEINS, AND COMPOSITIONS AND THERAPEUTIC METHODS THEREOF
    Publication number: 20220162280
    Abstract: The invention provides novel fusion proteins of Interleukin 12 and prodrugs, and compositions and methods of preparation thereof, useful in treating various diseases and disorders (e.g., hyperplasia, solid tumor or hematopoietic malignancy).
    Type: Application
    Filed: April 24, 2019
    Publication date: May 26, 2022
    Inventors: Yang-Xin Fu, Hua Peng, Diyuan Xue
  • TUMOR-SELECTIVE COMBINATION THERAPY
    Publication number: 20220160703
    Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in immunotherapy, particularly where the disease is accompanied by elevated levels of NQO1. In particular, embodiments where an immunotherapy, such as a heckpoint inhibitor, are combined with a NQO1 bioactivatable drug.
    Type: Application
    Filed: March 18, 2020
    Publication date: May 26, 2022
    Applicants: The Board of Regents of The University of Texas System, Indiana University Research and Technology Corporation, The Board of Trustees of the University of Illinois
    Inventors: Yang-Xin FU, Xiumei HUANG, David BOOTHMAN, Paul J. HERGENROTHER, Xiaoguang LI, Lingxiang JIANG
  • SEQUENTIAL TREATMENT OF CANCERS USING 6-THIO-dG, CHECKPOINT INHIBITORS AND RADIATION THERAPY
    Publication number: 20210290652
    Abstract: Disclosed herein are methods of treatments with a telomerase-mediated telomere-targeting drug, 6-thio-2?-deoxyguanosine (6-thio-dG), checkpoint inhibitors and/or radiation therapy for treating cancers. eads to tumor regression in innate and adaptive immune-dependent manners in syngeneic and humanized mouse cancer models.
    Type: Application
    Filed: March 12, 2021
    Publication date: September 23, 2021
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Jerry Shay, Yang-Xin Fu, Ilgen Mender, Anli Zhang
  • INTERFERON PRODRUG FOR THE TREATMENT OF CANCER
    Publication number: 20200123227
    Abstract: The present disclosure is directed to interferon prodrugs and their use in treating cancer. A particular advantage to such constructs is their ability to exert powerful anti-tumor activity in vivo reduction in many of the significant toxicities associated with interferon therapy.
    Type: Application
    Filed: June 18, 2018
    Publication date: April 23, 2020
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Yang-Xin FU, Xuezhi CAO
  • Anti-tumor therapy
    Patent number: 10421971
    Abstract: Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: September 24, 2019
    Inventors: Liufu Deng, Yang-xin Fu, Nikolai Khodarev, Ralph Weichselbaum
  • STING ACTIVATING NANOVACCINE FOR IMMUNOTHERAPY
    Publication number: 20190060446
    Abstract: In some aspects, the present disclosure provides vaccine compositions comprising an antigen and a diblock copolymer wherein the diblock copolymer is pH responsive. In some embodiments, these compositions activate the STING and/or the interferon receptor pathways. In some embodiments, the diblock copolymer hits a pKa from about 6 to about 7.5. Also provided herein are methods of treatment using these compositions to treat an infectious disease or cancer.
    Type: Application
    Filed: March 2, 2017
    Publication date: February 28, 2019
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Jinming GAO, Zhijian CHEN, Min LUO, Zhaohui WANG, Hua WANG, Haocheng CAI, Gang HUANG, Yang-Xin FU
  • Methods for cancer therapy using mutant light molecules with increased affinity to receptors
    Patent number: 10167328
    Abstract: Methods and compositions are disclosed to target tumor cells with embodiments of the LIGHT proteins linked fused or conjugated to a targeting agent. These compositions bind to both human and mouse receptors with affinity sufficient to conduct preclinical and clinical trials, and with increased affinity as compared to the wild type human LIGHT protein. The targeting of embodiments of LIGHT to tumor cells reduces tumor growth and reduces metastases.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 1, 2019
    Assignee: The University of Chicago
    Inventor: Yang-Xin Fu
  • METHODS AND COMPOSITIONS FOR CANCER THERAPY USING MUTANT LIGHT MOLECULES WITH INCREASED AFFINITY TO RECEPTORS
    Publication number: 20170137484
    Abstract: Methods and compositions are disclosed to target tumor cells with embodiments of the LIGHT proteins linked fused or conjugated to a targeting agent. These compositions bind to both human and mouse receptors with affinity sufficient to conduct preclinical and clinical trials, and with increased affinity as compared to the wild type human LIGHT protein. The targeting of embodiments of LIGHT to tumor cells reduces tumor growth and reduces metastases.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 18, 2017
    Inventor: Yang-Xin Fu
  • Antibody-light fusion products for cancer therapeutics
    Patent number: 9623116
    Abstract: Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: April 18, 2017
    Assignee: The University of Chicago
    Inventor: Yang-Xin Fu
  • ANTI-TUMOR THERAPY
    Publication number: 20160333355
    Abstract: Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.
    Type: Application
    Filed: October 24, 2014
    Publication date: November 17, 2016
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: Liufu Deng, Yang-xin Fu, Nikolai Khodarev, Ralph Weichselbaum
  • Compositions for cancer therapy using mutant light molecules with increased affinity to receptors
    Patent number: 9493532
    Abstract: Methods and compositions are disclosed to target tumor cells with embodiments of the LIGHT proteins linked fused or conjugated to a targeting agent. These compositions bind to both human and mouse receptors with affinity sufficient to conduct preclinical and clinical trials, and with increased affinity as compared to the wild type human LIGHT protein. The targeting of embodiments of LIGHT to tumor cells reduces tumor growth and reduces metastases.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: November 15, 2016
    Assignee: The University of Chicago
    Inventor: Yang-Xin Fu
  • INCREASED T-CELL TUMOR INFILTRATION AND ERADICATION OF METASTASES BY MUTANT LIGHT
    Publication number: 20160317631
    Abstract: Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and eradication of metastasis using mutant LIGHT are disclosed.
    Type: Application
    Filed: January 22, 2016
    Publication date: November 3, 2016
    Inventor: Yang-Xin Fu
  • METHODS AND COMPOSITIONS TO REDUCE LIVER DAMAGE ASSOCIATED WITH CONDITIONS OR THERAPIES THAT AFFECT THE IMMUNE SYSTEM
    Publication number: 20160250327
    Abstract: One side-effect arising from the use of antibodies against TNF receptor family members as therapeutics can be liver damage which precludes the completion of clinical trial. A novel LT-dependent pathway is described that mediates liver cell injury in several disease models.
    Type: Application
    Filed: March 28, 2016
    Publication date: September 1, 2016
    Inventor: Yang-Xin Fu
  • Increased T-cell tumor infiltration and eradication of metastases by mutant light
    Patent number: 9272025
    Abstract: Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and eradication of metastasis using mutant LIGHT are disclosed.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: March 1, 2016
    Assignee: The University of Chicago
    Inventor: Yang-Xin Fu
  • ANTIBODY-LIGHT FUSION PRODUCTS FOR CANCER THERAPEUTICS
    Publication number: 20150283260
    Abstract: Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases.
    Type: Application
    Filed: May 20, 2015
    Publication date: October 8, 2015
    Inventor: Yang-Xin Fu
  • Antibody-light fusion products for cancer therapeutics
    Patent number: 9061073
    Abstract: Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: June 23, 2015
    Assignee: The University of Chicago
    Inventor: Yang-Xin Fu
  • METHODS OF TREATING OBESITY
    Publication number: 20150157692
    Abstract: The present invention relates to methods of treating and/or preventing obesity comprising the administration of an inhibitor of lymphotoxin, IL-22 and/or IL-23 to a subject having or at risk of developing obesity.
    Type: Application
    Filed: May 23, 2013
    Publication date: June 11, 2015
    Inventor: Yang-Xin Fu
  • METHODS AND COMPOSITIONS FOR CANCER THERAPY USING MUTANT LIGHT MOLECULES WITH INCREASED AFFINITY TO RECEPTORS
    Publication number: 20150056219
    Abstract: Methods and compositions are disclosed to target tumor cells with embodiments of the LIGHT proteins linked fused or conjugated to a targeting agent. These compositions bind to both human and mouse receptors with affinity sufficient to conduct preclinical and clinical trials, and with increased affinity as compared to the wild type human LIGHT protein. The targeting of embodiments of LIGHT to tumor cells reduces tumor growth and reduces metastases.
    Type: Application
    Filed: December 11, 2012
    Publication date: February 26, 2015
    Inventor: Yang-Xin Fu
  • ANTIBODY-LIGHT FUSION PRODUCTS FOR CANCER THERAPEUTICS
    Publication number: 20120328558
    Abstract: Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases.
    Type: Application
    Filed: July 31, 2012
    Publication date: December 27, 2012
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventor: Yang-Xin Fu